GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (STU:29Y) » Definitions » Current Ratio

Spexis AG (STU:29Y) Current Ratio : 0.57 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Spexis AG's current ratio for the quarter that ended in Jun. 2023 was 0.57.

Spexis AG has a current ratio of 0.57. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Spexis AG has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Spexis AG's Current Ratio or its related term are showing as below:

STU:29Y' s Current Ratio Range Over the Past 10 Years
Min: 0.05   Med: 2.98   Max: 19.3
Current: 0.57

During the past 10 years, Spexis AG's highest Current Ratio was 19.30. The lowest was 0.05. And the median was 2.98.

STU:29Y's Current Ratio is ranked worse than
88.7% of 1548 companies
in the Biotechnology industry
Industry Median: 3.795 vs STU:29Y: 0.57

Spexis AG Current Ratio Historical Data

The historical data trend for Spexis AG's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Current Ratio Chart

Spexis AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.48 4.03 0.05 1.84 0.51

Spexis AG Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.84 1.15 0.51 0.57

Competitive Comparison of Spexis AG's Current Ratio

For the Biotechnology subindustry, Spexis AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spexis AG's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Current Ratio distribution charts can be found below:

* The bar in red indicates where Spexis AG's Current Ratio falls into.



Spexis AG Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Spexis AG's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=3.129/6.083
=0.51

Spexis AG's Current Ratio for the quarter that ended in Jun. 2023 is calculated as

Current Ratio (Q: Jun. 2023 )=Total Current Assets (Q: Jun. 2023 )/Total Current Liabilities (Q: Jun. 2023 )
=3.376/5.93
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spexis AG  (STU:29Y) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Spexis AG Current Ratio Related Terms

Thank you for viewing the detailed overview of Spexis AG's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Spexis AG (STU:29Y) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (STU:29Y) Headlines

No Headlines